Biofrontera’s 10% Ameluz topical gel, used with the BF-RhodoLED lamp series, won FDA approval for superficial basal cell carcinoma in adults. The indication expands Ameluz’s addressable market, and Biofrontera plans to launch through its existing commercial organization from late fourth quarter 2026 through first quarter 2027.

Key Highlights

  • Biofrontera plans to launch the new Ameluz indication from late fourth quarter 2026 through first quarter 2027.
  • Superficial basal cell carcinoma represents approximately 15%-20% of U.S. basal cell carcinoma cases, or an estimated 540,000 to 720,000 cases annually.
  • Ameluz PDT produced a 66% complete clinical and histological response rate versus 5% for placebo-PDT in the supporting trial.

Biofrontera Inc. (NASDAQ: BFRI) received FDA approval for its 10% Ameluz topical gel, used with the BF-RhodoLED lamp series to treat superficial basal cell carcinoma in adults. The approval makes Ameluz the first and only photodynamic therapy drug approved in the United States for a skin cancer.

Launch Plan Uses Existing PDT Footprint

The new indication uses the same Ameluz product and red-light device as Biofrontera’s actinic keratosis treatment. Existing customers can therefore adopt the option with their current equipment, while new dermatology practices may purchase a RhodoLED lamp and begin using Ameluz PDT. Biofrontera plans an official launch from late fourth quarter 2026 through first quarter 2027. The company plans to use its existing commercial organization and installed lamp base for the rollout.

Ameluz Market Opportunity and Trial Evidence

Approximately 3.6 million basal cell carcinoma cases are diagnosed annually in the United States. The superficial subtype represents approximately 15%-20% of basal cell carcinoma cases, equal to an estimated 540,000 to 720,000 cases each year. Complete clinical and histological response reached 66% with Ameluz PDT, compared with 5% with placebo-PDT. Histological clearance was 76% versus 19%, while complete clinical clearance of all target lesions reached 83% versus 21%.